Tucatinib (Tukysa) is a targeted therapeutic agent that demonstrates significant value in the treatment of HER2-positive breast cancer and colorectal cancer.

What Kind of Drug Is Tucatinib (Tukysa)?

Drug Class and Mechanism of Action

Tucatinib is a kinase inhibitor that specifically inhibits the HER2 receptor.

In in vitro experiments, the drug inhibits the phosphorylation of HER2 and HER3, thereby blocking the downstream MAPK and AKT signaling pathways and suppressing tumor cell proliferation.

Indication Scope

HER2-positive breast cancer: Used in combination with trastuzumab and capecitabine, it is indicated for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including those with brain metastases.

HER2-positive colorectal cancer: Used in combination with trastuzumab, it is indicated for the treatment of adult patients with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer.

Dosage Forms, Strengths, and Characteristics of Tucatinib (Tukysa)

Dosage Forms and Strengths

50 mg tablets: Round, yellow, engraved with "TUC" on one side and "50" on the other.

150 mg tablets: Oval, yellow, engraved with "TUC" on one side and "150" on the other.

Composition

Active ingredient: Tucatinib.

Tablet core excipients: Copovidone, crospovidone, sodium chloride, potassium chloride, sodium bicarbonate, colloidal silicon dioxide, magnesium stearate, and microcrystalline cellulose.

Coating ingredients: Yellow film coating, containing polyvinyl alcohol, titanium dioxide, polyethylene glycol (PEG), talc, and yellow iron oxide (non-irradiated).

Special Content Description

Each 50 mg Tucatinib tablet contains 10.10 mg (0.258 mEq) of potassium and 9.21 mg (0.401 mEq) of sodium.

Storage Methods for Tucatinib (Tukysa)

Storage Condition Requirements

Store at controlled room temperature between 20°C and 25°C (68°F and 77°F), with allowable fluctuations between 15°C and 30°C (59°F and 86°F).

Packaging and Handling Specifications

Storage in original container: The drug must be dispensed to patients in its original container.

Moisture-proof measures: Store in the original container to protect from moisture. After each opening, reclose the bottle cap tightly; do not discard the desiccant.

Shelf life after opening: The usable period after opening the bottle is 3 months.

Disposal of unused drug: Any unused tablets should be discarded 3 months after the bottle is opened.